Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion

BACKGROUND: The ETV6-NTRK3 gene fusion is present in the majority of cases of infantile fibrosarcoma (IFS) and acts as a potent oncogenic driver. We report the very rapid, complete, and sustained response of an advanced, chemotherapy-refractory, recurrent IFS to targeted treatment with the oral trop...

Descripción completa

Detalles Bibliográficos
Autores principales: Bielack, S S, Cox, M C, Nathrath, M, Apel, K, Blattmann, C, Holl, T, Jenewein, R, Klenk, U, Klothaki, P, Müller-Abt, P, Ortega-Lawerenz, S, Reynolds, M, Scheer, M, Simon-Klingenstein, K, Stegmaier, S, Tupper, R, Vokuhl, C, von Kalle, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859811/
https://www.ncbi.nlm.nih.gov/pubmed/31738425
http://dx.doi.org/10.1093/annonc/mdz382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859811/
https://www.ncbi.nlm.nih.gov/pubmed/31738425
http://dx.doi.org/10.1093/annonc/mdz382

Ejemplares similares